Model Introduction
Systemic Lupus Erythematosus (SLE) is a severe autoimmune disease characterized by immune dysregulation. Autoreactive cells and autoantibodies induce the excessive production of inflammatory cytokines and attack multiple organs and tissues, including the heart, joints, skin, lungs, blood vessels, liver, kidneys, and the nervous system. Epidemiological data shows a heavy disease burden for SLE in China, with an estimated incidence of approximately 8.57/100,000 person-years, ranking fourth globally. About 90% of patients are female, with the remainder being males and children. The 5-year survival rate for SLE patients improved from 50%–60% in the 1950s to over 90% in the 1990s and stabilized between 2008 and 2016. Despite advances in treatment and improved prognoses, SLE still carries high mortality and disability rates, and no cure currently exists, with its molecular pathogenesis not fully understood. In the study of SLE mechanisms and drug development, selecting appropriate animal models is of great significance. Existing SLE models are primarily divided into three categories: spontaneous models, induced models, and genetically modified models.
Research Applications
SLE animal models can be used to:
- Explore the pathogenesis of SLE.
- Study autoimmune dysregulation.
- Analyze the mechanisms of autoantibody production.
- Study immune complex nephritis.
- Evaluate the pharmacodynamics of anti-SLE drugs. Different models vary in their autoantibody profiles, renal pathological changes, and modes of immune activation, allowing for selection based on research goals.
Key Points of Experimental Design
I. Spontaneous SLE Animal Models Commonly used strains include:
- NZB/W F1 (NZBWE1/J) mice
- BXSB/MpJ mice
- MRL/MpJ-FasLpr/J mice These models do not require exogenous induction; lupus-like changes occur naturally as the animals age. II. Induced SLE Animal Models 1) Pristane-Induced Model
- Mechanism: Pristane is a medium-length alkane chain that acts as an adjuvant, triggering inflammation and enhancing the immune response. After intraperitoneal injection, pristane oil droplets are engulfed by monocyte-phagocytes, and T and B lymphocytes proliferate and aggregate to form granulomas. T cells become highly activated, and B cell reactivity increases, producing various autoantibodies. Some studies also suggest pristane induces apoptosis via mitochondrial damage, releasing nuclear antigens that initiate the autoimmune response.
- Evaluation and Application: Used for:
- SLE etiology and pathogenesis research.
- Immune regulation in autoimmune diseases.
- Immune complex nephritis research.
- Pharmacodynamic evaluation of anti-SLE drugs.
- Strain Differences:
- Different inbred strains vary in autoantibody probability and titer.
- BALB/cByJ, DBA/1, and C57BL/6J can produce anti-Su, anti-RNP/Sm (U1RNP), anti-dsDNA, anti-ssDNA, and anti-histone antibodies.
- A, SW, C57BL/6J, and SJL/J can produce anti-ribosomal P antibodies.
- Female mice are more susceptible to induced lupus-like lesions than males. 2) Activated Lymphocyte and Chromatin-Induced Model
- Mechanism: Immunizing syngeneic mice with activated inbred mouse lymphocytes as antigens can induce the host to produce anti-dsDNA antibodies, anti-nuclear antibodies, etc. Antigen-antibody complexes deposit in renal tissue, triggering immune complex glomerulonephritis similar to human lupus nephritis.
- Evaluation and Application: Used for:
- SLE pathogenesis research.
- Autoimmune regulation mechanism research.
- Immune complex nephritis research.
- Pharmacodynamic research for anti-SLE drugs.
Key Detection Indicators
1) Autoantibody Detection
- Anti-dsDNA antibodies
- Anti-ssDNA antibodies
- Anti-RNP/Sm antibodies
- Anti-Su antibodies
- Anti-histone antibodies
- Anti-ribosomal P antibodies 2) Immunological Changes
- T cell activation
- Increased B cell reactivity
- Changes in autoantibody titers 3) Organ Pathological Changes
- Immune complex deposition
- Manifestations of glomerulonephritis
